UroMems Boosts Leadership with Appointment of Rinda Sama to Board of Directors

UroMems Welcomes Rinda Sama to the Board of Directors

UroMems, a pioneer in the medical technology sector, known for developing cutting-edge solutions for stress urinary incontinence (SUI), has announced the significant addition of Rinda Sama to its board of directors. This appointment signals a strategic move as UroMems gears up for the launch of crucial clinical trials for its flagship product, the UroActive System – the first smart automated implant aimed at treating SUI.

A Seasoned Expert Joins the Ranks

Rinda Sama is no stranger to the medical device industry, boasting nearly two decades of experience, particularly in device manufacturing and operational excellence. Previously serving as the Chief Operating Officer at Axonics, Sama played an instrumental role in advancing sacral neuromodulation therapies that cater to patients with overactive bladder, a condition that profoundly affects millions.

UroMems' CEO, Hamid Lamraoui, expressed enthusiasm about Rinda's appointment, emphasizing that her extensive background in medical technology and operations will be a prized asset as the company embarks on its pivotal U.S. and European clinical trials.

Driving Innovation Forward

During her tenure at Axonics, Sama focused on optimizing operations and implementing stringent quality systems that ultimately paved the way for the company’s success, including receiving FDA approvals and a significant acquisition by Boston Scientific. Sama’s vast experience not only fosters regulatory success but also drives innovation that remarkably changes how patients receive medical care.

“I am thrilled to play a role in UroMems’ journey towards revolutionizing the treatment of stress urinary incontinence,” Sama stated. She likened UroMems' potential to that of Axonics, positioning it to deliver groundbreaking solutions to a market that has seen limited innovation for decades.

UroActive System: A Game Changer

The UroActive System is an active implantable electronic artificial urinary sphincter (AUS) set to deliver a much-needed treatment option for both men and women suffering from SUI. The technology utilizes a sophisticated mechatronic platform integrated with smart digital and robotic systems, tailoring treatment plans based on individual patient data. Such innovation aims to enhance both safety and efficacy, optimizing patient experiences while offering convenience to surgeons.

Currently, over 40 million Americans and an estimated 90 million Europeans are affected by SUI, which can severely impair quality of life, leading to depression and increased social stigma. Therefore, the successful roll-out of the UroActive System promises not only to improve health outcomes but also to uplift patient dignity and self-esteem.

Recent Milestones and Funding Success

UroMems has reported key achievements in its research and operational capacities, notably securing approximately $47 million in funding following the favorable results from a multicenter clinical study. This milestone represents a robust vote of confidence in UroMems’ mission and product potential: the first-ever female patient has also successfully received the smart automated AUS, marking a significant leap forward in the clinical application of their technology.

The appointment of Rinda Sama is poised to bolster UroMems as it continues to navigate through the complexities of FDA approvals while expanding its market influence in the healthcare space. With innovative therapies becoming increasingly vital, the addition of leadership talent like Sama heralds promising developments for UroMems and the patients it serves.

For further information about UroMems and its revolutionary products, visit www.uromems.com.